Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE38919 E1
Publication typeGrant
Application numberUS 10/458,806
Publication dateDec 13, 2005
Filing dateJun 11, 2003
Priority dateJun 23, 1993
Also published asDE69418286D1, DE69418286T2, EP0656203A1, EP0656203B1, EP0656203B3, US5676962, USRE40640, WO1995000120A1
Publication number10458806, 458806, US RE38919 E1, US RE38919E1, US-E1-RE38919, USRE38919 E1, USRE38919E1
InventorsJuan Cabrera Garrido, Juan Cabrera Garcia-Olmedo
Original AssigneeBtg International Limited
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Injectable microfoam containing a sclerosing agent
US RE38919 E1
Abstract
Injectable microfoam for sclerotcraphy. The sclerotherapy of varices is based on the injection of liquid substances capable of suppressing them. The present invention relates to the preparation of sclerosing substances in the form of a microfoam. The microfoam is prepared with sclerosing agents, and is then injected in the vein to be treated, so that the microfoam displaces the blood contained in the vein and provides for the contact of the sclerosing agent with the vascular endothelium, with a predetermined known concentration and during a controllable time.
Images(11)
Previous page
Next page
Claims(36)
1. Prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance.
2. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is polydocanol.
3. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is sodium tetradecyl sulfate.
4. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance is a hypertonic glucostated by glucosaline solution.
5. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is chromated glycerol.
6. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is ethanolamine oleate.
7. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is sodium morrhuate.
8. Injectable microfoam for therapeutic uses, according to claim 1, characterized in that the sclerosing substance used is any iodated solution.
9. A method for phlebologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
10. A method for phlebologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
11. A method for phlebologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
12. A method for treatment of esophageal varices comprising injecting the microfoam of claim 1 into vessels to be treated.
13. A method for treatment of esophageal varices comprising injecting the microfoam of claim 2 into vessels to be treated.
14. A method for treatment of esophageal varices comprising injecting the microfoam of claim 3 into vessels to be treated.
15. A method for proctologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
16. A method for proctologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
17. A method for proctologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
18. A method for angiologic treatment comprising injecting the microfoam of claim 1 into vessels to be treated.
19. A method for angiologic treatment comprising injecting the microfoam of claim 2 into vessels to be treated.
20. A method for angiologic treatment comprising injecting the microfoam of claim 3 into vessels to be treated.
21. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made in a container under pressure of oxygen.
22. The injectable microfoam of claim 21, wherein the at least one sclerosing substance is polidocanol.
23. The injectable microfoam of claim 21, wherein the microfoam further comprises at least one substance with a foaming capacity.
24. The injectable microfoam of claim 23, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
25. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made in a container under pressure of a mixture of oxygen and carbon dioxide.
26. The injectable microfoam of claim 25, wherein the at least one sclerosing substance is polidocanol.
27. The injectable microfoam of claim 25, wherein the microfoam further comprises at least one substance with a foaming capacity.
28. The injectable microfoam of claim 27, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
29. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made under pressure of oxygen in a hermetic container.
30. The injectable microfoam of claim 29, wherein the at least one sclerosing substance is polidocanol.
31. The injectable microfoam of claim 29, wherein the microfoam further comprises at least one substance with a foaming capacity.
32. The injectable microfoam of claim 31, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
33. An injectable microfoam for therapeutic use that is prepared or extemporaneously prepared comprising
at least one sclerosing substance chosen from polidocanol, sodium tetradecyl sulfate, hypertonic glucosated solutions, hypertonic glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, and iodated solutions, and
wherein the injectable microfoam is made under pressure of a mixture of oxygen and carbon dioxide in a hermetic container.
34. The injectable microfoam of claim 33, wherein the at least one sclerosing substance is polidocanol.
35. The injectable microfoam of claim 33, wherein the microfoam further comprises at least one substance with a foaming capacity.
36. The injectable microfoam of claim 35, wherein the at least one substance with a foaming capacity is chosen from polysorbate 20, polysorbate 80, and polygeline.
Description

This is a continuation of international application Serial No. PCT/ES94/00064, filed Jun. 21, 1994.

PRIOR ART

SchlerosisSclerosis of varices is based on injecting liquid substances in them, which causing a localized inflammatory reaction propitiates the elimination of these abnormal veins.

Upon injecting a sclerosing agent, a mixture thereof with the blood contained in the vein is produced and diluted in an unknown proportion. The results are uncertain (due to overdose or underdose) and limited to short varicose segments. As the size of the varices to be injected decreases, the lesser this dilution is and the results that are obtained are more foreseeable. Nowadays, sclerosis is a technique chosen in cases of small and medium-sized varices. Surgery is used for those varices with a diameter equal to larger than 7 mm.

Sclerosis and surgery complement each other at this time, but sclerotherapy continues without being able to be applied to large varicose trunci.

In these large sized varices, upon injecting a sclerosing substance, the concentration thereof in the vein, its homogenous distribution in the blood and the time that it is going to be in contact with the inside walls of the tretedtreated vein are unknown.

In 1946 Orbach injected in small caliber varices some few cubic centimeters of air and verified displacement of the blood inside the vessel, which is occupied by the injected air. The sclerosing agent introduced afterwards is more effective than if it has been injected into the blood.

In thick varices, upon injecting air, the described phenomenon of displacement of the blood by the injected air does not take place, but rather this forms a bubble inside the vein that makes the process ineffective in these vessels.

This same author conceived, a few years latelater, injection of foam obtained by agitating in a container containing sodium tetradecyl sulfate, an anionic sclerosing detergent with a high foaming capacity.

The process turns out to be rather useless due to the large-sized bubbles formed and dangerous due to the collateral effects of the atmospheric nitrogen, not very soluble in blood.

Both methods had very little practical repercussion as they were used only in small varices.

DESCRIPTION OF THE INVENTION

This invention refers to the preparation of a sclerosing microfoam.

In accordance with the present invention it has been discovered that injecting in a horizontal position a microfoam of pharmacologically inert sterile physiological serum, it is verified that the microfoam causes displacement of the blood contained in the vessel, even in more developed varices, due to the fact that the pressure of the blood contained in them horizontally is low.

The lifting of the injected member decreases even more the venous pressure, facilitating the exclusive filling of the vein with microfoam; this remaining in the vessel while the patient is not lifted from the examination table.

Upon replacing the prepared microfoam with the physiological serum by microfoam prepared with a sclerosing agent and injecting it in the vein, this displaces the blood that the vein contains and guarantees the contact of the sclerosis agent with the endothelium of the vein, at a known concentration and for a controllable amount of time, achieving sclerosis of the entire occupied segment.

The advantages of this process allow:

1. To know the concentration of the sclerosing agent in the vessel, as the microfoam displaces the blood and is not diluted in it like a liquid in it.

2. To guarantee the homogenous distribution of the product of sclerosis in the inside thereof.

3. To control the time in which it is kept in contact with the inside walls of the vein.

All of these factors are not known exactly nor are they controllable with the use of liquid sclerosing agents.

The elaboration of the present invention is carried out with the preparation of a microfoam with any sclerosing agent, such as: polydocanolpolidocanol, sodium tetradeclytetradecyl sulfate, hypertonic glucosated or glucosaline solutions, chromated glycerol, ethanolamine oleate, sodium morrhuate, iodated solutions.

Once the sclerosing microfoam has been prepared by any one of the existing processes, two of which will be described hereinafter, it is introduced in any sterile vessel that can be used later to be injected in the vessels to be treated, and that permits the stability of the same, so that it can be removed by a syringe, or by any other instrument that allows injection thereof into the vessels to be treated.

EXAMPLE 1

The preparation of the sclerosing microfoam is done by mixing in a sterile, hermetic container and connected if desired to a bottle under oxygen pressure, mixture of oxygen and carbon dioxide or other physiological gassesgases; mechanical beating is carried out by means of a micromotor that makes an écouvillon submerged in the sclerosing solution to be foamed turn.

Beating between 8,000 and 15,000 rpm, for a time between 60 and 120 seconds, the microfoam is achieved.

This is introduced into any container that can be used for subsequent storage and later injection into the veins to be sclerosed.

In the event that the sclerosing agent does not have a foaming capacity Polysorbate 20, Polysorbate 80, Polygeline or any other substance with a foaming capacity accepted as inert for intravenous use is added to it.

EXAMPLE 2

The sclerosing agent is introduced into a hermetic, pressurized and sterile container and by stirring the solution the microfoam is achieved, with a outlet from the container for its subsequent use.

The invention can also embrace prepared or extemporaneously prepared injectable microfoam for therapeutic uses characterized in that the microfoam is prepared with any sclerosing substance. In one embodiment, the sclerosing substanc in the injectable microfoam is polidocanol. In another embodiment, it is sodium tetradecyl sulfate. In a further embodiment, it is a hypertonic glucostated or glucosaline solution. In still another embodiment, the sclerosing substance can be chromated glycerol. The sclerosing substance in another embodiment is ethanolamine oleate. Another embodiment could envisage sodium morrhuate as the sclerosing substance. Still another, envisages any iodated solution.

The present invention also uses the inventive microfoam in phlebology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.

The present invention also uses the inventive microfoam in the treatment of esophageal varices. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.

The present invention also uses the inventive microfoam in a proctology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.

The present invention also uses the inventive microfoam in angiology. The sclerosing substance in the microfoam can be polidocanol or sodium tetradecyl sulfate.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3698453Dec 15, 1970Oct 17, 1972OrealDevice for storing two liquids separately and dispensing them simultaneously under pressure
US3970219Mar 3, 1975Jul 20, 1976Spitzer Joseph GAerosol containers for foaming and delivering aerosols and process
US4019657Mar 26, 1976Apr 26, 1977Spitzer Joseph GAerosol containers for foaming and delivering aerosols
US4040420Apr 22, 1976Aug 9, 1977General DynamicsPackaging and dispensing kit
US4127131Jun 20, 1977Nov 28, 1978Johnson & JohnsonHub assembly for use in the filtration of fluids and method of making the same
US4276885May 4, 1979Jul 7, 1981Rasor Associates, IncTumor detection
US4292972Jul 9, 1980Oct 6, 1981E. R. Squibb & Sons, Inc.Medical sponges, gelatin
US4466442 *Oct 13, 1982Aug 21, 1984Schering AktiengesellschaftCarrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics
US4718433Dec 5, 1985Jan 12, 1988Feinstein Steven BContrast agents for ultrasonic imaging
US5064103May 23, 1990Nov 12, 1991Rjs Industries, Inc.Foam dispenser having a plurality of sieves
US5084011Jan 25, 1990Jan 28, 1992Grady Daniel JMethod for oxygen therapy using hyperbarically oxygenated liquid
US5141738Mar 18, 1991Aug 25, 1992Schering AktiengesellschaftUltrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US5542935Nov 30, 1993Aug 6, 1996Imarx Pharmaceutical Corp.Apparatus for making therapeutic containing gas-filled liposomes
US5623085Jun 6, 1995Apr 22, 1997Rohm And Haas CompanyMethod for reducing microfoam in a spray-applied waterborne composition
US5656200Jan 14, 1994Aug 12, 1997Henkel Kommanditgesellschaft Auf AktienBased on alkyl oligoglycosides; cosmetic cleansers; biodegradability; dermatological compatibility
US5676962Feb 23, 1995Oct 14, 1997Cabrera Garrido; JuanInjectable microfoam containing a sclerosing agent
US5902225Apr 17, 1997May 11, 1999Monson; James A.Surfactants, post-foaming agents, compressed gas; for dispensing personal care cleaning compounds
US6561237Nov 28, 2000May 13, 2003Brasscorp Ltd.Apparatus and method for urging fluid into a pressurized system
CA1232837A1Apr 11, 1984Feb 16, 1988Jurgen HilmannUltrasound contrast agent containing microparticles and gas micro-bubbles
DE3048744A1Dec 23, 1980Jul 22, 1982Metzeler KautschukAnordnung zum abdichten einer mehrscheibenverglasung
DE3050812C2Dec 23, 1980Mar 21, 1985B. Braun Melsungen Ag, 3508 Melsungen, DeTitle not available
DE3417182C2May 9, 1984Jan 19, 1989Gerald Dr. 8000 Muenchen De HauerTitle not available
DE8704600U1Mar 27, 1987Oct 15, 1987Cocon Kunststoffen B.V., Arkel, NlTitle not available
DE69418286T2Jun 21, 1994Oct 14, 1999Btg Int LtdInjizierbarer Mikroschaum, der ein Verödungsmittel enthält
EP0054728A1Oct 30, 1981Jun 30, 1982Intermedicat GmbhCatheter assembly
EP0077752A2Oct 13, 1982Apr 27, 1983Schering AktiengesellschaftLiquid mixture for absorbing and stabilizing gas bubbles to be used as contrast agent in ultrasonic diagnosis and process for its preparation
EP0123235A2Apr 13, 1984Oct 31, 1984Schering AktiengesellschaftMicroparticles and ultrasonic contrast means containing gas bubbles
EP0131540A2Jul 5, 1984Jan 16, 1985Schering AktiengesellschaftContrast agent for ultrasounds and its preparation
EP0217582A2Sep 15, 1986Apr 8, 1987Unilever PlcPackage for mixing and dispensing
EP0324938A1Dec 6, 1988Jul 26, 1989Molecular Biosystems, Inc.Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
EP0359246A2Sep 13, 1989Mar 21, 1990Molecular Biosystems, Inc.Continuous sonication method for preparing protein encapsulated microbubbles
EP0656203A1Jun 21, 1994Jun 7, 1995Garrido Juan CabreraInjectable microfoam containing a sclerosing agent
EP0997396A1Sep 17, 1999May 3, 2000Kurt Vogelsang GmbHCap for two-components aerosol container
ES2068151A1 Title not available
FR1547768A Title not available
FR2672038A1 Title not available
FR2775436A1 Title not available
WO1992005806A1 *Sep 13, 1991Apr 6, 1992Sint SaMethod for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
WO1995000120A1Jun 21, 1994Jan 5, 1995Garrido Juan CabreraInjectable microfoam containing a sclerosing agent
WO1996025194A1Feb 12, 1996Aug 22, 1996Michael Paul BaylisMedication and apparatus and method of applying medication
WO1999043371A1Feb 12, 1999Sep 2, 1999Alain MonfreuxDevice for producing foam in a syringe body
WO2000024649A1Oct 22, 1999May 4, 2000Matthew Martin Derome CooperPackaging system for mixing and dispensing multicomponent products
WO2000066274A1Apr 28, 2000Nov 9, 2000Garcia Mingo Francisco JavierDevice for producing foamed sclerosing agent
WO2000072821A1May 26, 2000Dec 7, 2000Btg Int LtdGeneration of therapeutic microfoam
Non-Patent Citations
Reference
1A. Lemaire et al., "Effect of Intra-arterial oxygen injection on blood cholesterol", Therapie, vol. 13, pp. 395-399, 1958, with Abstract in English.
2A. Ochsner et al., "Comparative Value of Intravenous Sclerosing Substances", Archives of Surgery, vol. 29, No. 3, pp. 397-416, Sep. 1934.
3A. Schmler, "Clinical Comparison of Sclerosing Solutions in Injection Treatment of Varicose Veins, Delayed Slough: Recurrence of Varices", The American Journal of Surgey, vol. XXXVI, No. 1, pp. 389-398, Apr. 1937.
4B. Ya Varshavskii, "Mechanism of Changes in Renal Activity Following intravenous oxygen", vol. 53, No. 2, pp. 173-177, 1967, with Abstract in English.
5De L'Academie des Sciences, Conformement A Une Decision de L'Academie, pp. 890-892, Jan. 1930 and translation into English.
6DVD #1 and #2 containing video clips shown during interview of Jan. 7, 2004.
7E. J. Orbach, "Contributions to the Therapy of the Varicose Complex", Journal of the International College of Surgeons, pp. 765-771, Jun. 1950.
8E. J. Orbach, "The Place of Injection Therapy in the Treatment of Venous Disorders of the Lower Extremity-with Comments on its Technique", Presented at the Annual Meeting of the International College of Angiology, London, pp. 18-23, Jul. 1965.
9E. Orbach, "Leg Ulcers of Vascular Origin and Their Therapy" The American Journal of Surgery, vol. LXXXI, No. 5, pp. 568-572, May 1951.
10E.J. Orbach et al.; "The Thrombogenic Property of Foam of a Synthetic Anionic Detergent (Sodium Tetradecyl Sulfate N.N.R.)", Angiol 1, pp. 237-243; 1950.
11E.J. Orbach, "Schlerotherapy of Varicose Veins", American Journal of Surgery, vol. LXVI, No. 3, pp. 362-366, Dec. 1944.
12E.J. Orbach; "Sclerotherapy of Varicose Veins-Utilization of an Intravenous Air Block"; American Journal of Surgery; vol. LXVI, No. 3, pp. 362-366; Dec. 1944.
13F.B. Cockett, "Arterial Complications during Surgery and Sclerotherapy of Varicose Veins", Phlebology, vol. 1, pp. 3-6, 1986.
14F.W. Runnicliffe et al., "The Intravenous Injection of Oxygen Gas as a Therapeutic Measure", Lancet, vol. II, pp. 321-323, 1916, with Abstract in English.
15G. de Takats et al., "Division of the Popliteal Vein In Deep Venous Insufficiency of the Lower Extremities", Society for Vascular Surgery Issue, vol. 29., No. 3, pp. 342-354, Mar. 1951.
16G. de Takats et al., "The Injection Treatment of Varicose Veins", Surgery, Gynecology and Obstetrics, vol. L, No. 3, pp. 545-561, Mar. 1930.
17G. de Takats, "Ambulatory Ligation of the Saphenous Vein", The Journal of the American Medical Association, vol. 94, No. 16, pp. 1194-1197, Apr. 19, 1930.
18G. Galata, "Intravenous Injection of Oxygen in Dogs", Archivio di Fisiologia, vol. 21, pp. 331-350, 1923, with Abstract in English.
19G. Mayer, "The Treatment of Varicose Veins from the point of View of Sclerotherapy, in particularly on the Basis of Varicophtine", Münchener Medizinische Wochenschrift, vol. 16, No. 20, Columns 1037-1039, Jan. 1952 and translation into English.
20G. Miserey et al., "Sclerose Sous Echographie Dans Certaines Zones a Risques", Phlebologie, vol. 44, No. 1, pp. 85-96, 1991.
21German Nullity Action Complaint filed Jul. 27, 2001 and translation into English.
22German Nullity Action Decision by German Court in English dated Feb. 4, 2003.
23German Nullity Action English Translation of the Substantiation of Appeal to the Federal Court of Justice on Sep. 26, 2003.
24German Nullity Action First Brief filed Dec. 3, 2001 and translation into English.
25German Nullity Action Kreusler Brief filed Jan. 27, 2003 and translation into English.
26German Nullity Action Supplemental Brief filed Dec. 31, 2002 and translation into English.
27German Nullity Action; English Translation of the Reply to appeal dated Feb. 12, 2004.
28H. Biegeleisen, "Fatty Acid Solutions for the Injection Treatment of Varicose Veins", Annals of Surgery, vol. CV, pp. 610-615, 1937.
29H. Harkins et al., "Embolism by Air and Oxygen: Comparative Studies", Proceedings of the Society for Experimental Biology and Medicine, vol. 32, pp. 178-181, 1934-35.
30H. Jausion, "Glycerine Chromee et Sclerose des Ectasies Veineuses", La Presse Medicale, No. 53, pp. 1061-1063, Jul. 5, 1933.
31H. Leonhardt, "On the Treatment of Extensive Formation of Varicose Veins with Ligature of the v. Saphena and Varicoid Injection Through Ditally Inserted Ureteral Catheter", Ärztliche Wochenschrift, vol. 7, No. 3, pp. 56-58, Jan. 1952 and translation into English.
32H. Rogge, "On the dangers of sclerosing recurring varicose veins", Deutsche Medizinische Wochenschrift, No. 9, p. 301, 1950 and translation into English.
33H. Wefers et al., "Results of Injection Treatment with Regard to Extreme Varication", Zentralblatt für Chirurgie, Issue No. 43, pp. 1825-1828, 1952 and translation into English.
34H.E. Lockhart-Mummery et al., "Varicose Ulcer-A Study of the Deep Veins with Special Reference to Retrograde Venography", The British Journal of Surgery, vol. XXXVIII, No. 151, pp. 284-295, Jan. 1951.
35H.G. Oden, "Can the Results of the Treatment of Varicose Vains and Ulcus Cruris be Improved?", Münchener, Medizinische Wochenschrift, vol. 22, No. 8, pp. 364, Jan. 1952 and translation into English.
36I. Singh, "Life Without Breathing", Arch. int. Pharmacodyn., vol. CXXXVII, No. 3-4, pp. 318-330, 1962.
37I.S. Tunick et al., "Sodium Morrhuate as a Sclerosing Agent in the Treatment of Varicose Veins", Annals of Surgery, vol. XCV, pp. 734-737, 1932.
38Jan-Christoph G.R. Wollmann, MD, "The History of Sclerosing Foams", Dermatol Surg. vol. 30, No. 5, pp. 694-703, May 2004.
39K. Biegeleisen et al., "Inadvertent Intra-Arterial Injection Complicating Ordinary and Ultrasound-Guided Sclerotherapy", Phlebology, vol. 19, pp. 953-958, 1993.
40K. Sigg, "Newer Aspects of the Technique of Treating Varicosities", Therapeutishce Umschau, vol. 6, pp. 127-134, 1949 and translation into English.
41K. Sigg, "The Foamed Rubber Compression for Phlebitis and for Phlebitic and Varicose Complications", Die Medizinische, No. 27-28, pp. 910-915, Jul. 1952 and translation into English.
42K. Sigg, "The Treatment of Varicosities and Accompanying Complications", Angiology, The Journal of Vascular Diseases, vol. 3, No. 5, pp. 355-379, Oct. 1952.
43K10-E. Rabe et al.; "Guidelines to Sclerosing Treatment of Varicose Veins"; Leitlinien der DGP, Phlebologie; vol. 6, pp. 154-158; 2001 and translation into English.
44K11-DE 3417182 C2 and EP 0 054 728 and translations into English.
45K12-K. Sigg, "Newer Aspects of the Technique of Treating Varicosities", Therpeutishce Umschau, vol. 6, pp. 127-134, 1949 and translation into English.
46K13-M. Schadeck; "Duplex Controlled Sclerosing Treatment of the Great Saphenous Vein"; Phlebol; vol. 25, pp. 78-82; 1996 and translation into English.
47K14-R. Rowden-Foote; "Varicose Veins Hemorrhoids and Other Conditions-Their Treatment by Injection"; London, H.K. Lewis & Co. Ltd.; pp. 13-45, 106-119; 1944.
48K15-A. Ree; "The Treatment of Varicose Veins with Etamolin Foam"; Acta Dermato-Venereologica; vol. 39, pp. 428-432; 1959.
49K16-E.J. Orbach et al.; "The Thromobogenic Property of Foam of a Synthetic Anionic Detergent (Sodium Tetradecyl Sulfate N.N.R.)", Angiol 1, pp. 237-243; 1950.
50K17-M.D.H.-D. Bock; "Varicosis and its Therapy"; Ärztliche Praxis; XIX vol., No. 60, pp. 2146-2148; Jul. 29, 1967 and translation into English.
51K18-O. Henschel;"Die Varizenverördening-Verördungstherapie mit Aethoxysklerol-Kreussler"; p. 22; 1968 and translation into English.
52K19-13 Pr. Dr. rer. nat. Reinhard Höhler ; "The Expression <<Micro Foam>> is Neither Generally Known to Experts in the Field nor Well-defined"; Laboratoire de Physique de Milieux Diviséet Interfaces Université de Marne-la-Vallée and translation into English.
53K1-Von P. Flückiger, "Nicht-operative retrograde Varicenverödung mit Varsylschaum", Schweizerische Medizinische Wochenschrift, No. 48, pp. 1368-1370, (1956) with English translation.
54K20-Chronologia der Schaumverödung.
55K21-J. Orbach, "Sclerotherapy of varicose Veins", American Journal of Surgery, vol. LXVI, No. 3, pp. 362-366, Dec. 1944.
56K22-J.R. Cabrera Garrido et al., "Extending the Limits of Sclerotherapy: New Sclerosing Products", Phlébp;pgoe, vol. 50, No. 2, pp. 181-188, 1997.
57K23-J. Cabrera; "Application Techniques for Sclerosant in Micro-Foam Form"; pp. 39-44.
58K24-Video (VHS) tape of Compression Sclerotherapy, H.R., Bernbach, M.D. and English Translation of the Documentation Accompanying the Video K24; pp. 1-16.
59K25-Dr. J.C. Wollmann et al.; Evaluation of the Test; Kreussler Pharma; pp. 17-28, Jan. 29, 2003.
60K26-Pr. Dr. R. Höhler ; "The Indication of the Rotation Speed and the Duration of the Rotation is not Sufficient for Foams Produced by a Rotating Brush to be Able to Produce a Foam that Has Well-Defined Properties and that Can Be Reproduced."; and translation into English.
61K27-Pr. Dr. R. Höhler; "Comparison Between Three-Dimensional Foams and Two-Dimensional Foams Which Are Produced by Squashing a Three-Dimensional Foam between a Two-Dimensional Foam."; Laboratoire de Physique de Milleux Divisés et Interfaces Université de Marne-la-Vallée and translation into English.
62K2-H. Mayer et al., "On the aetiology and treatment of varices of the lower extremities", Angiology, Chirurgische Praxis, pp. 521-528, (1957) with English translation.
63K3-Meyers'Encyclopedia, 5<SUP>th </SUP>Edition, vol. 15, pp. 386 (1985) with English translation.
64K4-Von P. Flückiger et al., "Beitrag sur Technik der ambulanten Varizenbehandlung", No. 12, pp. 617-621, Mar. 23, 1963.
65K5-Dr. Med. Jo{hacek over (ze Baridevic; "Varicosclerozation in Phlebological Practice"; The Journal for Doctors, in Clinical and Practice; XXI vol. No. 3, pp. 126-136; Jan. 11, 1989, and translation into English.
66K6-W. Gillesberger; "The Equipment of the Dermatologist Working in the Field of Phlebology", the Journal for Skin Diseases; vol. 44 (18), pp. 669-674; 1969 and translation into English.
67K7-Dr. E. Lunkenheimer; Letter to Chem. Fabrik Kreussler & Co.; Mar. 20, 1967 and translation into English.
68K8-Gianni Belcaro; "Micro-sclerotherapy"; Sclerotherapy in Venous Disease; pp. 89-95; 2002.
69K9-M. Schadeck; "Ultrasound-controlled Sclerotherapy of the Great Saphenous Veins"; Phlébologie; vol. 46, No. 4, pp. 673-682, 1993 and tranlsation into English.
70L. Ferguson, "Ligation of Varicose Veins, Ambulatory Treatment Preliminary to Sclerosing Injections", Annals of Surgery, vol. CII, pp. 304-314, 1935.
71L. Karmazsin et al., "Experimental Study of Lipid Peroxidation Following Intravenous Oxygen", Kiserletes Orvostudomany, vol. 39, pp. 342-348, 1987, with Abstract in English.
72L. Moszkowiez, "Treatment of Varicose Veins with Sugar Injections, combined with vein ligation", Zentralblatt fur Chirurgie, No. 28, pp. 1731-1736, 1927 and translation into English.
73L. Reiner, "The Activity of Anionic Surface Active Compounds in Producing Vascular Obliteration", Surface Active Sclerosing Agents, Proceedings of the Society for Experimental Biology and Medicine, vol. 62, pp. 49-54, May-Jun. 1946.
74M. Battezzati et al., "Treatment of Lower Limb Varices with Multiple Endermic Ligations and Sclerosant Injections Combined or not with Stripping of the Long Saphenous Vein's higher region", Minerva Chirurgica, pp. 936-939, 1952 and translation into English.
75M. Mairano, "Metodo combinato chirurgico-sclerosante o metodo sclerosante semplice nel trattamento delle varici essenziali?" Minerva Chirugica, vol. VI, No. 16, pp. 244-247, May 1951.
76M. Schadeck et al., "Echotomographie de la Sclerose", Phlebologie, vol. 44, No. 1, pp. 111-130, 1991.
77Meyers's Encyclopedia 5<SUP>th </SUP>Edition, 1895, vol. 15, pp. 386.
78P. Jaeger, "The Current Treatment Standard for Crural Ulcer and Varices", Deutsche Medizinische Wochenschrift, vol. 77, No. 14, pp. 421-425, Apr. 4, 1952 and translation into English.
79P. Piulaches et al., "Pathogenic Considerations on Varicose Veins Developed in Pregnancy", Lyon Chirurigical, Bulletin official de la Socirte de Chriurgie de Lyon, vol. 47, No. 3, pp. 263-278, Apr. 1952 and translation into English.
80P. Thibault et al., "Recurrent Varicose Veins", Phlebology, vol. 18, pp. 895-900, 1992.
81R. Bayeux, "Comparative Resistance of Dog and Rabbit to Intravenous Injection of Oxygen", Compt. Rend. vol. 156, pp. 1329-1331, 1913, with Abstract in English.
82R. de Somer-Leroy et al., "Echographie du Creux-Poplite Recherche D'Une Arteriole Petite Saphene Avant Sclerotherapie", Phlebologie, vol. 44, No. 1, pp. 69-78, 1991.
83R. E. Weston et al., "The Influence of Denitrogenation on the Response of Anesthetized Dogs to Intravenously Injected Oxygen", vol. 26, pp. 837-848, 1946.
84R. Foote, "Treatment", Varicose Veins, Chapter 5, p. 65 and 86, 1949.
85R. Jung, "Injection Treatment of Varicose Veins", Praxis, 195-198, 1950 and translation into English.
86R. M. Knight et al., "Ultrasonic Guidance of Injections into the Superficial Venous System", Phlebology, pp. 339-341, 1989.
87R. Rowden-Foote; "Varicose Veins Hermorrhoids and Other Conditions-Their Treatment by Injection"; London, H.K. Lewis & Co. Ltd.; pp. 13-45, 106-119; 1944.
88R. Zingg, "Experimental tests with the new sclerosing agent "Geigy"", pp. 1-9, 1948.
89R.M. Moore et al., "Injections of Air and Carbon Dioxide into a Pulmonary Vein", Annals of Surgery, vol. 112, pp. 212-218, 1940.
90R.S. Handley, "The Treatment of Varicose Veins", The Practitioner-Diseases of the Veins, No. 993, vol. 166, pp. 228-235, Mar. 1951.
91S. Efuin et al., "Oxygen Parameters of Blood and Tissues during Intravascular Oxygenation of the Organism", Eksperimental'naya Khirurgiya I Anesteziologiya, vol. 5, pp. 183-186, 1974, with Abstract in English.
92S. Efuin et al., Oxygen Parameters of Blood and Tissues during Intravascular Oxygenation of the Organism, Eksperimental'naya Khirurgiya I Anesteziologiya, vol. 5, pp. 71-74, 1974, with Abstract in English.
93Sigg, "Regarding treatment of varicose veins and their complications", Dermatologica, vol. 100, p. 317, 1950 and translation into English.
94V. Gorisch et al., "Appearance of intravenously given radioactive oxygen in expired air", Naunyn-Schmiedebergs Archiv fuer Experimentelle Pathologie und Pharmakologie, vol. 238, pp. 106-107, 1960, with Abstract in English.
95V. Gorisch et al., "Expiration of labeled oxygen after intravenous insufflation", Medicina Experimentalis, vol. 1, pp. 333-338, 1959, Abstract in English.
96Vin, "Echo-Sclerotherapy of the Small Saphenous Vein", Phlebologie, vol. 44, No. 1, pp. 79-84, 1991 with Abstract in English.
97W. Heyerdale et al., "Management of Varicose Veins of the Lower Extremities", Annals of Surgery, vol. 114, pp. 1042-1049, 1941.
98Written commentary tracking the DVDs submitted herein.
99Z.B. Shafi et al., "Factors Affecting High Shear Preparation of Albumin Microspheres", Pharmaceutical Sciences Research GRoup, p. 144P, 1990.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7604185Sep 14, 2005Oct 20, 2009Btg International Ltd.Generation of therapeutic microfoam
US7731986Nov 17, 2004Jun 8, 2010Btg International Ltd.comprises a sclerosant liquid, e.g. polidocanol solution, and a gas e.g. O2 or CO2; by inter alia causing a localised inflammatory reaction, favor the elimination of varicose veins and other disorders involving venous malformation
US7763269Nov 17, 2004Jul 27, 2010Btg International Ltd.Therapeutic foam
US7842282Oct 13, 2006Nov 30, 2010Btg International Limiteduse in sclerotherapy of blood vessels; from medical device, injecting a mixture of blood dispersible gases carbon dioxide and/or oxygen, and a sclerosing agent polidocanol, foaming in blood veins; avoiding use of potentially hazardous amounts of nitrogen; treating varicose veins disorder; drug delivery
US7842283Oct 13, 2006Nov 30, 2010Btg International Limiteduse in sclerotherapy of blood vessels; from a device, injecting a mixture of blood dispersible gases carbon dioxide and/or oxygen, and a sclerosing agent polidocanol, foaming in blood veins; avoiding use of potentially hazardous amounts of nitrogen; treating varicose veins disorder; drug delivery device
US8048439May 13, 2005Nov 1, 2011Btg International Ltd.Therapeutic foam
US8091801Jun 18, 2009Jan 10, 2012Btg International LimitedGeneration of therapeutic microfoam
US8323677Apr 23, 2010Dec 4, 2012Btg International Ltd.is generated and delivered simultaneously using a syringe based device; comprises a sclerosant liquid, polidocanol solution, and gas N2, xenon; by inter alia causing a localised inflammatory reaction, favor the elimination of varicose veins; low density; half-life
US8512680Jul 16, 2007Aug 20, 2013Btg International Ltd.Injectables in foam, new pharmaceutical applications
US8703827May 12, 2006Apr 22, 2014Btg International Ltd.Therapeutic foam
Classifications
U.S. Classification424/423, 424/484, 424/422
International ClassificationA61K9/12, A61F2/01
Cooperative ClassificationY10S514/945, Y10S424/07, A61K9/122
European ClassificationA61K9/12B